Literature DB >> 6431261

Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.

D W Kufe, D Munroe, D Herrick, E Egan, D Spriggs.   

Abstract

1-beta-D-Arabinofuranosylcytosine (ara-C) incorporates into DNA, and the extent of this incorporation correlates significantly with inhibition of DNA synthesis. The incorporated ara-C residue provides a poor primer terminus for further chain elongation. There is a highly significant relationship between formation of (ara-C) DNA and loss of clonogenic survival. The present studies confirm that incorporation of ara-C into DNA, and not the competitive inhibition of DNA polymerase, is responsible for inducing lethal cellular events. The results also demonstrate that the incorporated ara-C residue is not excised from the DNA strand. Furthermore, the presistence of ara-C residues in DNA inhibits recovery of DNA synthesis following exposure to drug. The relative DNA chain-terminating effect of ara-C provides several mechanisms of action that explain internucleotide and chain terminus positioning of ara-C residues, reinitiation of previously replicated DNA segments, and DNA strand or chromosomal breaks. The precise mechanism of action is dependent upon dose scheduling of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431261

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

Review 1.  The vaccinia virus DNA polymerase and its processivity factor.

Authors:  Maciej W Czarnecki; Paula Traktman
Journal:  Virus Res       Date:  2017-02-01       Impact factor: 3.303

2.  Cytarabine-induced destabilization of a model Okazaki fragment.

Authors:  W H Gmeiner; A Skradis; R T Pon; J Liu
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

Review 3.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

4.  The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.

Authors:  L M Wang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Authors:  Eric R Gamazon; Jatinder K Lamba; Stanley Pounds; Amy L Stark; Heather E Wheeler; Xueyuan Cao; Hae K Im; Amit K Mitra; Jeffrey E Rubnitz; Raul C Ribeiro; Susana Raimondi; Dario Campana; Kristine R Crews; Shan S Wong; Marleen Welsh; Imge Hulur; Lidija Gorsic; Christine M Hartford; Wei Zhang; Nancy J Cox; M Eileen Dolan
Journal:  Blood       Date:  2013-03-28       Impact factor: 22.113

6.  ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Authors:  Brett Ewald; Deepa Sampath; William Plunkett
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

7.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.